The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vu, M. D.
Right arrow Articles by Li, X. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vu, M. D.
Right arrow Articles by Li, X. C.
The Journal of Immunology, 2004, 173: 214-221.
Copyright © 2004 by The American Association of Immunologists

Different Costimulatory and Growth Factor Requirements for CD4+ and CD8+ T Cell-Mediated Rejection 1

Minh Diem Vu2,*, Farhana Amanullah2,*, Yongsheng Li*, Gulcin Demirci*, Mohamed H. Sayegh{dagger} and Xian Chang Li3,*

* Department of Medicine, Harvard Medical School, Division of Immunology, Beth Israel Deaconess Medical Center, and {dagger} Transplantation Research Center, Brigham and Women’s Hospital and Children’s Hospital, Harvard Medical School, Boston, MA 02215

Costimulatory signals and growth factor signals play a key role in commanding T cell activation and T cell effector function. However, how costimulatory signals and growth factor signals interact and integrate into the activation program of CD4+ and CD8+ T cells during the allograft response remains poorly defined. In the present study we found that either CD4- or CD8-deficient mice can vigorously reject the skin allografts. Blocking rapamycin-sensitive growth factor signals produced long term skin allograft survival in CD4-deficient mice (mean survival time, >120 days), but not in CD8-deficient mice (mean survival time, 20 days). Analysis of CFSE-labeled cells proliferating in the allogeneic hosts revealed that clonal expansion of CD4+ T cells in vivo was more resistant to growth factor blockade than that of CD8+ T cells. However, blockade or genetic absence of CD28/CD154 costimulatory molecules rendered CD4+ T cell-mediated rejection sensitive to rapamycin, and long term skin allograft survival can be readily induced by rapamycin in the absence of CD28/CD154 signals (>100 days). Furthermore, blocking OX40 costimulation induced long term skin allograft survival in CD4-deficient mice and CD8-deficient mice when both CD28 and CD154 were transiently blocked. We conclude that CD4+ and CD8+ T cells exhibit distinct sensitivity to growth factor blockade in transplant rejection, and CD28/CD154-independent rejection is sensitive to rapamycin and appears to be supported by OX40 costimulation.




This article has been cited by other articles:


Home page
J. Immunol.Home page
B. E. Burrell, G. Lu, X. C. Li, and D. K. Bishop
OX40 Costimulation Prevents Allograft Acceptance Induced by CD40-CD40L Blockade
J. Immunol., January 1, 2009; 182(1): 379 - 390.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. Elyaman, P. Kivisakk, J. Reddy, T. Chitnis, K. Raddassi, J. Imitola, E. Bradshaw, V. K. Kuchroo, H. Yagita, M. H. Sayegh, et al.
Distinct Functions of Autoreactive Memory and Effector CD4+ T Cells in Experimental Autoimmune Encephalomyelitis
Am. J. Pathol., August 1, 2008; 173(2): 411 - 422.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Song, T. So, and M. Croft
Activation of NF-{kappa}B1 by OX40 Contributes to Antigen-Driven T Cell Expansion and Survival
J. Immunol., June 1, 2008; 180(11): 7240 - 7248.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. E. Gelman, M. Okazaki, J. Lai, C. G. Kornfeld, F. H. Kreisel, S. B. Richardson, S. Sugimoto, J. R. Tietjens, G. A. Patterson, A. S. Krupnick, et al.
CD4+ T Lymphocytes Are Not Necessary for the Acute Rejection of Vascularized Mouse Lung Transplants
J. Immunol., April 1, 2008; 180(7): 4754 - 4762.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Zhai, Y. Wang, Z. Wu, and J. W. Kupiec-Weglinski
Defective Alloreactive CD8 T Cell Function and Memory Response in Allograft Recipients in the Absence of CD4 Help
J. Immunol., October 1, 2007; 179(7): 4529 - 4534.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
G. Yu, X. Xu, M. D. Vu, E. D. Kilpatrick, and X. C. Li
NK cells promote transplant tolerance by killing donor antigen-presenting cells
J. Exp. Med., August 7, 2006; 203(8): 1851 - 1858.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Verdeil, D. Puthier, C. Nguyen, A.-M. Schmitt-Verhulst, and N. Auphan-Anezin
STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors.
J. Immunol., April 15, 2006; 176(8): 4834 - 4842.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. D. Vu, M. R. Clarkson, H. Yagita, L. A. Turka, M. H. Sayegh, and X. C. Li
Critical, but Conditional, Role of OX40 in Memory T Cell-Mediated Rejection
J. Immunol., February 1, 2006; 176(3): 1394 - 1401.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Battaglia, A. Stabilini, and M.-G. Roncarolo
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Blood, June 15, 2005; 105(12): 4743 - 4748.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. J. Fox, P. S. Hammerman, and C. B. Thompson
The Pim kinases control rapamycin-resistant T cell survival and activation
J. Exp. Med., January 18, 2005; 201(2): 259 - 266.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. Metzler, P. Gfeller, M. Bigaud, J. Li, G. Wieczorek, C. Heusser, P. Lake, and A. Katopodis
Combinations of Anti-LFA-1, Everolimus, Anti-CD40 Ligand, and Allogeneic Bone Marrow Induce Central Transplantation Tolerance through Hemopoietic Chimerism, Including Protection from Chronic Heart Allograft Rejection
J. Immunol., December 1, 2004; 173(11): 7025 - 7036.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.